Announcements Trials
Browse Landscape

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 13Observational 2

Sponsor

Cancer Type

Breast 2

Conditions

ESR1 Gene Mutation 1Breast Neoplasms 1

Interventions

Blood Specimen Collection 31Sorafenib 29Nivolumab 29Bevacizumab 26Data Collection 24Observation 23palbociclib 22Sunitinib 22radium Ra 223 dichloride 20enzalutamide 18Rituximab 18Ipilimumab 16regorafenib 15Drug Therapy 15Trastuzumab 14Docetaxel 14ribociclib 12exemestane 12atezolizumab 12Standard of Care 12darolutamide 11apalutamide 11Leuprolide 11Capecitabine 11Afatinib 11Bortezomib 10Anastrozole 10trastuzumab deruxtecan 9pembrolizumab 9avelumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Observational × elacestrant × Clear all
NCT07563595 2026-05-04

ELENI

iOMEDICO AG

Not yet recruiting
500 enrolled
Breast

Breast Neoplasms

NCT06544577 2024-08-09

Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBC

SciClone Pharmaceuticals

Recruiting
350 enrolled
Breast

ESR1 Gene Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡